Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2026)
Lyell Immunopharma (LYEL) reported Profit After Tax of -$24.4 million for Q1 2026, up 53.24% on a YoY basis from -$15.9 million in Q1 2025, and up 82.66% sequentially from -$140.8 million in Q4 2025.
Lyell Immunopharma (LYEL) Profit After Tax (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Profit After Tax data on file, last reported at -$24.4 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 53.24% year-over-year to -$24.4 million; the trailing twelve-month figure through Mar 2026 stood at -$246.6 million (up 26.14% YoY), and the FY2025 full-year result was -$274.5 million, up 19.88% from the prior year.
- Profit After Tax advanced to -$24.4 million in Q1 2026, from -$140.8 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$6.0 million in Q4 2022 to a low of -$192.4 million in Q4 2024.
- A 5-year average of -$62.2 million and a median of -$52.2 million in 2025 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax surged 92.99% in 2022 and plunged 782.17% in 2023, its largest moves.
- Tracing LYEL's Profit After Tax over 5 years: stood at -$6.0 million in 2022, then tumbled by 782.17% to -$52.9 million in 2023, then plunged by 263.51% to -$192.4 million in 2024, then rose by 26.84% to -$140.8 million in 2025, then soared by 82.66% to -$24.4 million in 2026.
- Business Quant data shows LYEL's Profit After Tax at -$24.4 million in Q1 2026, -$140.8 million in Q4 2025, and -$38.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Lyell Immunopharma | 298.14 Mn | 298.14 Mn | - | -24.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.40 Mn |
| Dec 31, 2025 | -140.77 Mn |
| Sep 30, 2025 | -38.70 Mn |
| Jun 30, 2025 | -42.68 Mn |
| Mar 31, 2025 | -52.20 Mn |
| Dec 31, 2024 | -192.40 Mn |
| Sep 30, 2024 | -43.43 Mn |
| Jun 30, 2024 | -45.81 Mn |
| Mar 31, 2024 | -60.67 Mn |
| Dec 31, 2023 | -52.93 Mn |
| Sep 30, 2023 | -49.66 Mn |
| Jun 30, 2023 | -63.89 Mn |
| Mar 31, 2023 | -66.96 Mn |
| Dec 31, 2022 | -6.00 Mn |
| Sep 30, 2022 | -71.90 Mn |
| Jun 30, 2022 | -36.32 Mn |
| Mar 31, 2022 | -68.14 Mn |
| Dec 31, 2021 | -85.59 Mn |
| Sep 30, 2021 | -48.88 Mn |
| Jun 30, 2021 | -62.60 Mn |